Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteome Systems has ceased the development of a diagnostic test for prostate cancer. This decision is based on the results of a proof of concept study which demonstrated that the project did not satisfy internal assessment hurdles.
Subscribe to our email newsletter
Following validation by Proteome Systems of data generated by Egenix, which demonstrated increased expression of HCA (human carcinoma antigen) in cancerous versus non-cancerous prostate tissues, the proof of concept study evaluated the merits of HCA as a semen-based diagnostic marker for prostate cancer.
Proteome Systems identified a protein that provides prostate-specific detection of HCA in semen, and developed an assay for detection of HCA in clinical samples. However, the company found that commercialization of the assay would require significant resources along with an extended development timeline.
Jenny Harry, CEO of Proteome Systems, said: “We remain committed to projects with near-term revenue potential, as well as leveraging existing intellectual property in the fields of respiratory and infectious diseases.
“In particular, we are exploring opportunities to expand the development of products using our DiagnostIQ platform.”